Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 12 and 13, 2025, under a pre-arranged trading plan.
Summary
- Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on February 12, 2025, at a weighted average price of $11.49.
- He also sold 2,000 shares of common stock on February 13, 2025, at a weighted average price of $11.69.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, Ma indirectly owns 2,871,260 shares through his spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the stock sales were pre-planned under a 10b5-1 trading plan.
Industry Context
Sales by company presidents are common and are often part of personal financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information.
Stakeholder Impact
- The stock sales could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2024-09-13 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-02-12 | Date of first stock sale |
| 2025-02-13 | Date of second stock sale |
| 2025-02-14 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.